Researchers presenting at the American Society of Clinical Oncology (ASCO) conference on Sunday introduced an experimental oral drug designed to treat pancreatic cancer [1].

This development is significant because the drug targets a mutated protein that has eluded medical treatment for decades. Pancreatic cancer remains one of the most lethal forms of the disease due to a lack of effective targeted therapies.

The experimental medication, called daraxonrasib, works by blocking a specific mutated protein that drives tumor growth [1]. Researchers said this specific protein mutation is present in more than 90% of pancreatic cancer cases [1]. By inhibiting this protein, the drug aims to slow the progression of the disease in patients with advanced stages of cancer.

The findings were shared during the ASCO conference on June 1, 2026 [2]. The drug is administered orally, which may provide a more accessible treatment option compared to traditional intravenous chemotherapy. Early reports from the presentation suggest the drug has shown signs of extending survival for patients who have limited remaining options.

Medical professionals have long struggled to find a "druggable" target for pancreatic tumors. The high prevalence of this specific mutation across the patient population suggests that daraxonrasib could have a broad impact if it passes subsequent clinical trials [1].

While the results are promising, the drug remains in the experimental phase. Further large-scale studies are required to determine the long-term efficacy, and safety profile of the treatment before it can be approved for general clinical use [1].

“The experimental medication, called daraxonrasib, works by blocking a specific mutated protein that drives tumor growth.”

The identification of a viable target in over 90% of pancreatic cancer cases represents a shift toward precision medicine for a disease that has historically resisted targeted therapy. If daraxonrasib proves effective in later trials, it could transform the standard of care from broad-spectrum chemotherapy to a targeted oral treatment, potentially increasing survival rates for a majority of patients.